01
Cash & equivalents decreased 65.6%
Cash & equivalents changed -65.6% from the comparable as-filed period.
$183.1M→$63.0MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTAltimmune, Inc.'s latest supported as-filed period reports revenue of $41,000, 0.0% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -65.6% from the comparable as-filed period.
Net income changed -3.1% from the comparable as-filed period.
Operating income changed -14.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ALT · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001698665-26-000007SEC ↗10-QAug 12, 2026Period Jun 30, 20260001326190-26-000052SEC ↗8-KAug 12, 2026Period Aug 12, 20260001326190-26-000049SEC ↗4Aug 3, 2026Period Jul 31, 20260001251779-26-000009SEC ↗4Aug 3, 2026Period Jul 31, 20260001705905-26-000010SEC ↗8-KJul 28, 2026Period Jul 28, 20260001326190-26-000044SEC ↗8-KJun 16, 2026Period Jun 16, 20260001104659-26-074575SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 13, 2026Filed Aug 13, 2026 | Durso Jerome BenedictPresident and CEO | Open Market PurchaseDirect | 15,000 | $3 | $44,250 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +8.2% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Revenue changed +0.0% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Stock-based compensation changed -21.8% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001326190-26-000040